On January 13th and 14th, the Global Alliance for Patient Access (GAfPA) and Agora, a platform of organizations of people with rheumatic diseases in Southern Europe, held a workshop in Budapest for patient advocates. The aim of this event was to provide patient groups with a greater understanding of the current landscape for biologic and … Continued
Data from a clinical study in Norway may soon explain the effects of switching stable patients from a biologic medicine, infliximab, to its biosimilar counterpart. But, as the Global Alliance for Patient Access argues in a new white paper, policymakers must accurately interpret what the NOR-SWITCH study will – and will not – demonstrate about the … Continued
En 2015, la Organización Mundial de la Salud (OMS) anunció su propuesta de denominación de medicamentos biosimilares que son similares, pero no idénticos para referenciar a los medicamentos biológicos. La propuesta de la OMS sugiere que los biológicos de referencia y biosimilares tienen un nombre/ denominación común internacional (INN) que los cualifica usando al azar … Continued
Patient advocates have teamed up to take an important message to European physicians and policymakers: distinct names for biosimilar medications are essential. The Global Alliance for Patient Access and the Alliance for Safe Biologic Medicines recently presented posters at two European health policy meetings. The posters feature survey data from physicians to highlight the need … Continued
GAfPA and Alliance for Safe Biologics poster presentation, 20th International Congress of Parkinson’s Disease and Movement Disorders; MDS Congress 2016
Patient safety is a very important subject for the European Crohn’s and Ulcerative Colitis Associations (EFCCA) and the Global Alliance for Patient Access (GAfPA), and lies at the core of our work. Within this framework EFCCA, together with GAfPA, organised an advocacy workshop on patient safety, which took place in Barcelona from 4-6 February 2016. … Continued
GAfPA and Alliance for Safe Biologics poster presentation at EULAR 2016
More at National Physicians Biologics Working Group